The immunological status of children with epilepsy and the potential use of delta sleep-inducing peptide for immunocorrection

The immunological status of 102 children with epilepsy aged 3 to 14 years was analyzed in a placebo-controlled study evaluating the efficacy of delta sleep-inducing peptide as part of combined treatment. Suppression of T-cell immunity and reduced neutrophil phagocytic activity were identified. The effects of delta sleep-inducing peptide were assessed using clinical, instrumental and laboratory measures. Patients with epilepsy showed a reduction in the frequency of acute respiratory infections and recovery of absolute leukocyte and lymphocyte counts and the CD3+, CD8+ and CD16+ subpopulations.